ACO/ARO/AIO-22:外照射联合腔内高剂量率近距离放疗用于老年和虚弱直肠癌患者
ACO/ARO/AIO-22是一项前瞻性多中心对照试验,纳入年龄≥70岁和/或虚弱的非转移性直肠腺癌患者,先接受EBRT 13×3 Gy(总39 Gy),再行腔内HDR-BT 3×8 Gy(总24 Gy)或CXB 90 Gy分3次。主要终点为治疗开始后12个月的cCR或ncCR,次要终点为EORTC QLQ-ELD14测量的生活质量。
要点
- 纳入标准:年龄≥70岁和/或虚弱,cT1-3d N0/+ M0,肿瘤距肛缘0-16 cm,无法接受根治性手术。
- EBRT方案为13×3 Gy(总39 Gy),疗程两周半;EBRT完成后6.5周重新分期。
- HDR-BT为每周3次×8 Gy至总24 Gy(处方于肿瘤径向边缘,最大处方深度10 mm),或CXB 90 Gy分3次。
核心结论
- 该前瞻性多中心试验将评估EBRT联合腔内HDR-BT在老年和/或虚弱直肠癌患者中的器官保留率和生活质量。
研究设计与样本
- ACO/ARO/AIO-22为前瞻性多中心对照试验,纳入年龄≥70岁和/或虚弱的非转移性直肠腺癌患者。
- 纳入条件包括cT1-3d N0/+ M0、mrCRM -/+、肿瘤距肛缘0-16 cm且无法接受根治性手术。
主要发现
- 初始治疗为EBRT 13×3 Gy(总39 Gy),疗程两周半。
- EBRT完成后6.5周重新分期,随后行腔内HDR-BT 3次每周8 Gy至总24 Gy(处方于肿瘤径向边缘,最大处方深度10 mm),或CXB 90 Gy分3次每周。
- 主要终点为治疗开始后12个月的cCR或ncCR,第二主要终点为EORTC QLQ-ELD14测量的生活质量。
关键数值与推荐
- EBRT剂量:13×3 Gy,总39 Gy,疗程两周半。
- HDR-BT剂量:3次每周8 Gy,总24 Gy,处方于肿瘤径向边缘,最大处方深度10 mm。
- CXB剂量:90 Gy分3次每周。
- 主要终点:治疗开始后12个月的cCR或ncCR。
临床怎么用
- 对于无法接受根治性手术的老年和/或虚弱直肠癌患者,可考虑EBRT联合腔内HDR-BT或CXB的器官保留策略。
- 治疗后12个月评估cCR或ncCR以及EORTC QLQ-ELD14生活质量。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Rectal cancer disproportionately affects the elderly population, with more than half of cases diagnosed in individuals aged 70 years or older. Frail patients in this group often face significant challenges tolerating the standard treatment of total mesorectal excision (TME), due to elevated risks of surgical complications and perioperative morbidity. Advances in radiotherapy techniques offer a viable alternative, providing effective tumor control while minimizing treatment-related toxicity. Recent clinical trials, including OPERA and MORPEUS, have demonstrated that dose-escalated radiotherapy, which integrates external beam (chemo)radiotherapy (EBRT) with high-dose-rate endorectal brachytherapy (HDR-BT) or contact X-ray brachytherapy (CXB), can achieve high clinical response rates and facilitate organ preservation in younger, healthier patient cohorts. Building on these findings, the ACO/ARO/AIO-22 study seeks to adapt these innovative approaches to meet the needs of elderly and frail patients with rectal cancer. METHODS/DESIGN: The ACO/ARO/AIO-22 trial is a prospective multicentre controlled trial. Elderly (age ≥70 years) and/or frail patients with non-metastatic rectal adenocarcinoma (cT1-3d N0/+ M0, mrCRM - / +) localized 0-16 cm from the ano-cutaneous line, unable to undergo radical surgery can be included. The initial treatment comprises an external beam radiation (EBRT) regime with 13 × 3 Gy (total: 39 Gy) over a period of two and a half weeks. Following initial restaging 6.5 weeks after completion of EBRT, endorectal HDR-BT will be delivered with 3 weekly fractions of 8 Gy to a total dose of 24 Gy (prescribed at the radial margin of the tumor; with a maximum prescription depth of 10 mm); alternatively, with CXB with 90 Gy in 3 weekly fractions. The primary objective is complete or near complete clinical response (cCR or ncCR) and the second primary endpoint is quality of life (QoL) measured with the EORTC QLQ-ELD14, both at 12 months after treatment start. DISCUSSION: The ACO/ARO/AIO-22 prospective multicentre trial will evaluate organ preservation rates and QoL after combining EBRT with endorectal HDR-BT in elderly and/or frail patients with rectal cancer.Trial Registration:Clinicialtrials.gov number: NCT06729645.
引用
- Dapper H, Fleischmann M, Tselis N, et al. ACO/ARO/AIO-22 - External beam radiotherapy combined with endorectal high-dose-rate brachytherapy in elderly and frail patients with rectal cancer: A prospective multicentre trial of the German Rectal Cancer Study Group. Clin Transl Radiat Oncol. 2025. PMID: 40276115. doi:10.1016/j.ctro.2025.100958
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。